ViAqua

ViAqua

Delivering the power of RNA therapeutics to aquaculture

Sector Animal Health

Founded 2014

Headquarters Park Gutwirth, Technion city, Haifa

ViAqua Therapeutics was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. One of the major challenges facing the shift to sustainable aquaculture practice is the prevention and treatment of disease. With the annual loss from disease reaching nearly 20% of revenues, there is an acute need for development and introduction of new technologies.

Current treatments depend primarily on antibiotics or non-specific chemicals that may have deleterious environmental effects. Many state of the art treatments, such as vaccines, are still administered by injection, a costly at best or non-feasible administration route for crustaceans’ and some fish species.

ViAqua is developing a biotechnology-based, oral delivery platform for targeted administration of nucleic acid-based therapeutics. ViAqua’s first product is an RNA based solution for application against the White Spot Shrimp Virus (WSSV) pandemic.

headshot.png
LEADERSHIP
Image-empty-state.png
Shai Ufaz, Ph.D.

CEO & Co-Founder

Image-empty-state.png
Shai Einbinder, Ph.D.

Co-Founder

ARTICLES
Food ID Post Cover.png

06/20/20

Congratulations to our World Economic Forum Technology Pioneers 2020

Sanjeev Krishnan, S2G Ventures Managing Director and CIO, will ...Connecting Technology and Business to Create Healthy, Resilient Food Systems. 

Read Time

X

min

Read More
IN THE NEWS

6/10/21

ViAqua gets $4.3 million investment from S2G Ventures and Thai Union for shrimp health platform

S2G Ventures, Thai Union and Agriline have invested $4.3 million in ViAqua Therapeutics to help develop its RNA-based shrimp health platform and bring other health and nutrition projects closer to commercialisation.

The Fish Site

OUR PODCAST

WHERE DO WE GROW FROM HERE
VIEW MORE COMPANIES